Imugene (ASX:IMU) Science Series, Cellular Therapy – With Paul Woodard, MD & John Byon, MD PhD

2 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Our latest Science Series dives into autologous and allogeneic CAR T-cell therapy and the evolving treatment landscape for diffuse large B-cell lymphoma (DLBCL). Dr. Paul Woodard, Chief Medical Officer, and Dr. John Byon, Senior VP Clinical Development, discuss the differences between autologous and allogeneic CAR T-cell therapies, how azer-cel is designed to overcome limitations in current treatments, and the latest promising trial results showing a 57% complete response rate.


#Imugene #IMU #ASX #CancerResearch #Oncology #CAR-T #CellTherapy #CancerTreatment #ScienceSeries #OncolyticVirus #Immunotherapy #CancerSurvivorship #DrugDevelopment #CancerInnovation #Biotechnology #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
Category
Oncology
Be the first to comment

Up Next